Table 2.
Demographics and baseline characteristics.
| n (%) | Treatment group (mITT population) |
||||
|---|---|---|---|---|---|
| ADAM zolmitriptan |
|||||
| Placeboa n = 77 | 1 mg n = 79 | 1.9 mg n = 83 | 3.8 mg n = 82 | Total n = 321 | |
| Female | 69 (89.6) | 70 (88.6) | 73 (88.0) | 68 (82.9) | 280 (87.2) |
| Age, mean (SD) years | 42.7 (11.5) | 41.7 (11.6) | 40.1 (10.9) | 41.0 (11.4) | 41.3 (11.3) |
| Race | |||||
| White | 59 (76.6) | 58 (73.4) | 54 (65.1) | 67 (81.7) | 238 (74.1) |
| MBS | |||||
| Nausea | 20 (26.0) | 17 (21.5) | 19 (22.9) | 17 (20.7) | 73 (22.7) |
| Phonophobia | 21 (27.3) | 21 (26.6) | 22 (26.5) | 22 (26.8) | 86 (26.8) |
| Photophobia | 36 (46.8) | 41 (51.9) | 42 (50.6) | 43 (52.4) | 162 (50.5) |
a
Consisted of pooled 1-patch and 2-patch placebo groups.